const NeuralNetworksCancerRemediation = () => (
  <article>
    <p>
      During my senior year at Central Connecticut State University, I wrote and published a
      thesis exploring a question that sits at the intersection of AI, robotics, and medicine:
      could neural network-guided bio-nanorobots be used to detect and treat cancer at the
      cellular level? This post walks through the core architecture, the neural network models
      involved, and the real-world constraints that make this a hard problem.
    </p>

    <h2>The Problem with Current Cancer Treatment</h2>
    <p>
      Conventional cancer treatments — chemotherapy, radiation — are powerful but imprecise.
      They operate on bulk tissue rather than individual cells, which means healthy cells
      inevitably suffer collateral damage. The appeal of nanorobotics is specificity: agents
      small enough to navigate the human body, locate malignant cells, and deliver a targeted
      response without disturbing surrounding healthy tissue.
    </p>
    <p>
      The question my thesis addressed wasn't whether this is physically possible (nanorobotics
      is an active hardware research area), but whether a viable computational framework could
      be designed — one that uses modern neural network architectures to handle the core tasks
      of navigation, detection, and treatment.
    </p>

    <h2>Architecture Overview</h2>
    <p>
      The proposed system has three functional layers, each driven by a different class of
      neural network:
    </p>
    <ol>
      <li><strong>Body traversal</strong> — nanorobots navigating via Relation Structure-Aware Heterogeneous Graph Neural Networks (RSHNs)</li>
      <li><strong>Cancer cell detection</strong> — a dual-channel Convolutional Neural Network (CNN) fed by nano-optic cameras</li>
      <li><strong>Targeted treatment</strong> — pharmacyte drug delivery upon confirmed detection</li>
    </ol>

    <h2>Layer 1 — Navigation: Heterogeneous Graph Neural Networks</h2>
    <p>
      The human body is a fundamentally heterogeneous environment — veins, arteries, lymphatic
      vessels, and tissue boundaries are structurally distinct, and a nanorobot navigating
      through them must reason about relationships that differ in kind, not just degree. The
      thesis models this as a <strong>heterogeneous graph</strong>, where nodes represent
      anatomical locations and edges encode the different types of relationships between them.
    </p>
    <p>
      To extract meaningful traversal decisions from this graph, the framework uses{' '}
      <strong>Relation Structure-Aware Heterogeneous Graph Neural Networks (RSHNs)</strong> —
      a GNN architecture specifically designed for heterogeneous graphs. Unlike standard GNNs,
      RSHNs are relation-structure aware: they capture multi-relational associations across
      node types, allowing the model to reason about biologically distinct path types rather
      than collapsing them into a uniform edge representation.
    </p>
    <p>
      The thesis evaluates three nanorobot traversal strategies against each other:
    </p>
    <ul>
      <li><strong>Wiggle traversal</strong> — oscillating lateral movement; slowest and least efficient</li>
      <li><strong>Saltatory traversal</strong> — jump-based movement through discrete waypoints; middle performance</li>
      <li><strong>Wandering traversal</strong> — adaptive pathfinding guided by the RSHN model; fastest and most accurate</li>
    </ul>
    <p>
      Wandering traversal, powered by the RSHN, consistently outperformed the alternatives by
      exploiting the full relational structure of the body graph rather than relying on
      fixed movement patterns.
    </p>

    <h2>Layer 2 — Detection: Dual-Channel CNNs and Nano-Optic Cameras</h2>
    <p>
      Once nanorobots reach target tissue, cancer detection becomes an imaging problem. Each
      nanorobot is equipped with a <strong>nano-optic (meta-optic) camera</strong> — a
      miniaturized imaging device capable of capturing cellular-scale data from inside the body.
      The feed from this camera is processed by a <strong>dual-channel CNN</strong>.
    </p>
    <p>
      The dual-channel architecture uses two parallel input streams — enabling the model to
      process complementary feature representations simultaneously. The network consists of
      four convolutional layers and three subsampling (pooling) layers, and was benchmarked at{' '}
      <strong>95.85% classification accuracy</strong> on cancer cell detection. CNNs are
      well-suited here because malignancy identification is fundamentally a spatial pattern
      recognition task: the same feature extraction mechanisms that power image classification
      translate directly to identifying the morphological signatures of cancerous cells.
    </p>

    <h2>Layer 3 — Treatment: Pharmacytes</h2>
    <p>
      Upon CNN-confirmed detection, the nanorobots act as <strong>pharmacytes</strong> —
      purpose-built drug-delivery nanorobots measuring <strong>1–2 micrometers in diameter</strong>,
      with onboard drug reservoirs of 1–3μm. Each pharmacyte is equipped with capacitors for
      power storage, molecular motors for propulsion, and micro-cameras for local navigation.
      Treatment is administered by releasing a targeted therapeutic payload directly at the
      malignant cell.
    </p>
    <p>
      Because treatment is triggered only after CNN-confirmed identification, healthy tissue is
      not exposed to the therapeutic agent. The pharmacyte model also allows for adaptive
      dosing: swarm size, payload concentration, and release timing can be tuned dynamically
      based on detected cancer cell density, rather than applying a fixed systemic dose.
    </p>

    <h2>Legal and Ethical Considerations</h2>
    <p>
      Any system operating autonomously inside a patient's body carries serious legal and
      ethical weight, and the thesis addresses these directly.
    </p>
    <ul>
      <li>
        <strong>HIPAA Title II</strong> — Biosensor and imaging data collected inside a
        patient is protected health information. Any real implementation must enforce strict
        data governance over what is transmitted, to whom, and how it is stored and audited.
      </li>
      <li>
        <strong>ACM Code of Ethics §1.2</strong> — Autonomous medical AI systems must avoid
        harm. The nanorobot framework must be explainable and contestable: a physician should
        be able to audit why the CNN flagged a cell as malignant before the pharmacyte
        administers treatment.
      </li>
      <li>
        <strong>Asimov's First Law applied to nanorobotics</strong> — A nanorobot must not
        harm a human or, through inaction, allow harm to occur. The thesis uses this as a
        framing principle for designing safe failure modes — when confidence is below threshold,
        the system should defer to a physician rather than act autonomously.
      </li>
      <li>
        <strong>Informed consent and incidental findings</strong> — Deploying nanorobots inside
        a patient requires explicit consent covering the scope of autonomous decision-making.
        A harder problem is incidental findings: if the system detects something outside its
        treatment mandate, what does it do? The thesis flags this as an open ethical question
        requiring clear policy before deployment.
      </li>
    </ul>

    <h2>Where This Stands</h2>
    <p>
      This is a conceptual and computational framework — not a clinical implementation. The
      hardware side (manufacturing and deploying pharmacyte-scale nanorobots at therapeutic
      scale) remains a major open problem in materials science and bioengineering. But the
      value of this kind of systems-level thinking is that it surfaces the hard constraints
      early: model size, latency, explainability, and consent aren't afterthoughts you can
      bolt on later — they have to be designed in from the start.
    </p>
    <p>
      The intersection of AI and nano-scale medicine is one of the areas I find most
      compelling, precisely because the stakes are real and the engineering challenges are
      genuinely hard. If you want to read the full thesis, it's published in the CCSU
      library catalog:
    </p>
    <p>
      <a
        href="https://cscu-ccsu.primo.exlibrisgroup.com/discovery/delivery/01CSCU_CCSU:CCSU_V1/12119319420003453"
        target="_blank"
        rel="noopener noreferrer"
      >
        Neural Network-Guided Nanobots for Cancer Remediation — CCSU Library
      </a>
    </p>
  </article>
);

export default NeuralNetworksCancerRemediation;
